By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Resverlogix Corporation 

4820 Richard Road SW
Suite 300
Calgary  Alberta  T3E 6L1  Canada
Phone: 403-254-9252 Fax: 403-256-8495


Company News
Resverlogix (RVX.TO) Presents New Data At The European Society of Cardiology Congress 2015 On RVX-208 'Apabetalone' A Selective BET Inhibitor 8/31/2015 7:19:40 AM
International Clinical Steering Committee Announced For Resverlogix (RVX.TO)'s Phase 3 Betonmace Clinical Trial With RVX-208 "Apabetalone" 8/4/2015 6:09:31 AM
Resverlogix (RVX.TO) Closes $50 Million Private Placement With Hepalink And Eastern Capital 7/21/2015 10:52:36 AM
Resverlogix (RVX.TO) Closes License Agreement And Enters Into Definitive Stock Purchase Agreement With Shenzhen Hepalink Pharmaceutical Co., Ltd 7/8/2015 6:33:22 AM
Resverlogix (RVX.TO) Shareholders Approve Matters Relating To Licensing And Equity Arrangement 7/1/2015 8:16:16 AM
Resverlogix (RVX.TO) Officially Attains Phase 3 Status With A European Regulatory Authority 6/22/2015 7:37:02 AM
BIO2015: Resverlogix (RVX.TO) To Present At The 2015 BIO International Convention 6/17/2015 8:55:43 AM
Resverlogix (RVX.TO) Reports On The Beneficial Effects Of RVX-208 On Glucose Metabolism In Prediabetes Mellitus At The American Diabetes Association's (ADA) Scientific Sessions In Boston, MA 6/8/2015 10:00:07 AM
Resverlogix (RVX.TO) Presents New Data At 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 6/1/2015 7:41:58 AM
Resverlogix (RVX.TO) CEO Says It's in Talks With Suitors, After $100M in Q1 Deals 4/28/2015 6:32:05 AM